Lupin Ltd Update on Biotech manufacturing facility

The U.S. FDA conducted a Prior-Approval Inspection at Lupin's Biotech manufacturing facility in Pune, India in October 2022. The inspection concluded with the issuance of a Form 483 with seventeen observations. We are committed to addressing the concerns raised by the U.S. FDA expeditiously.

The Company does not believe that the 483 letter will have an impact on the existing revenues from operations of this facility.

Shares of Lupin Limited was last trading in BSE at Rs. 678.90 as compared to the previous close of Rs. 688.10. The total number of shares traded during the day was 96524 in over 1922 trades.

The stock hit an intraday high of Rs. 691.00 and intraday low of 670.65. The net turnover during the day was Rs. 65869069.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 PriorApprovalInspection BiotechManufacturingFacility Pune India